Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisha Tang

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Biomaterials|January 8, 2025
Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targetingFangfang Jin, Xingyu Wei, Yongcan Liu, et al.
Frontiers in Oncology|February 25, 2022
Mutant NPM1-Regulated FTO-Mediated m<sup>6</sup>A Demethylation Promotes Leukemic Cell Survival <i>via</i> PDGFRB/ERK Signaling AxisQiaoling Xiao, Li Lei, Jun Ren, et al.
Journal for Immunotherapy of Cancer|July 15, 2025
Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemiaYongcan Liu, Jiayuan Hu, Yan Shu, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 22, 2024
Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemiaJun Ren, Junpeng Huang, Zailin Yang, et al.
Plos Genetics|April 28, 2017
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancerXiaofeng Jin, Jie Wang, Kun Gao, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Biomaterials|January 8, 2025
Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targetingFangfang Jin, Xingyu Wei, Yongcan Liu, et al.
Frontiers in Oncology|February 25, 2022
Mutant NPM1-Regulated FTO-Mediated m<sup>6</sup>A Demethylation Promotes Leukemic Cell Survival <i>via</i> PDGFRB/ERK Signaling AxisQiaoling Xiao, Li Lei, Jun Ren, et al.
Journal for Immunotherapy of Cancer|July 15, 2025
Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemiaYongcan Liu, Jiayuan Hu, Yan Shu, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 22, 2024
Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemiaJun Ren, Junpeng Huang, Zailin Yang, et al.
Plos Genetics|April 28, 2017
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancerXiaofeng Jin, Jie Wang, Kun Gao, et al.
Pageof 6